Comparing Denali Therapeutics (DNLI) and Recro Pharma (REPH)

Denali Therapeutics (NASDAQ: DNLI) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.


This table compares Denali Therapeutics and Recro Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Denali Therapeutics N/A N/A N/A
Recro Pharma -69.61% -75.97% -21.65%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Denali Therapeutics and Recro Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics 0 1 3 0 2.75
Recro Pharma 0 1 5 0 2.83

Denali Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 18.93%. Recro Pharma has a consensus target price of $14.42, suggesting a potential upside of 41.76%. Given Recro Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe Recro Pharma is more favorable than Denali Therapeutics.

Valuation & Earnings

This table compares Denali Therapeutics and Recro Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics N/A N/A -$86.65 million N/A N/A
Recro Pharma $71.83 million 2.71 -$50.08 million ($2.65) -3.84

Recro Pharma has higher revenue and earnings than Denali Therapeutics.

Institutional and Insider Ownership

65.5% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Recro Pharma shares are owned by institutional investors. 21.6% of Recro Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Recro Pharma beats Denali Therapeutics on 6 of the 10 factors compared between the two stocks.

Denali Therapeutics Company Profile

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company‚Äôs development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Recro Pharma Company Profile

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply